Company Eris Lifesciences Limited Bombay S.E.

ERIS

INE406M01024

Pharmaceuticals

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Group companies

Sector

Ratings for Eris Lifesciences Limited

EPS Revisions

Quarterly revenue - Rate of surprise

Sector Other Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 06:00:49 2024-04-23 am EDT			5-day change	1st Jan Change
882 ^INR	-0.18%		+1.66%	-3.14%

Apr. 03	Eris Lifesciences Completes Acquisition of Biocon Biologics' India Formulation Business	MT
Mar. 15	Eris Lifesciences to Acquire India Formulation Business of Biocon Biologics for INR12.42 Billion	MT

Eris Lifesciences Limited is an India-based company that is primarily engaged in the manufacturing and marketing of pharmaceutical products. The Companyâs manufacturing plant is located in Guwahati, Assam. Its therapeutic areas include oral diabetes care, cardiac care, pain/analgesics, gynecology, gastrointestinal, central nervous system (CNS), and vitamins, minerals, and nutrients (VMN). The Company's brands include Advog 0.2, Atorsave Gold 10, Baga NT 100, Calshine 60K Tablet, Carpela, Cilentra Plus 5, Cognix, D1000cal, Enoxsave 60, Glimisave M 4 forte, Levroxa 1000, Mac Rabonik Plus, Glimisave, Eritel, Renerve, Tendia, Olmin, Rabonik, Tayo, Cyblex, Lnbloc, Remylin, Zomelis, Crevast, Atorsave, Ginkocer and Metital. The Companyâs wholly owned subsidiaries include Kinedex Healthcare Private Limited, Aprica Healthcare Limited, and Eris Healthcare Private Limited.

Number of employees: 3,548

INR in Million	2022	Weight	2023	Weight	Delta
Pharmaceuticals 100.0 %	13,470	100.0 %	16,851	100.0 %	+25.10%

INR in Million	2022	Weight	2023	Weight	Delta
India 100.0 %	13,470	100.0 %	16,851	100.0 %	+25.10%

Managers	Title	Age	Since
Amit Indubhushan Bakshi CEO	Chief Executive Officer	50	07-01-26
Vijay S. Joshi PSD	President	-	10-04-30
Sachin Shah DFI	Director of Finance/CFO	44	12-12-31
Krishnakumar Vaidyanathan COO	Chief Operating Officer	49	20-12-19
Milind Talegaonkar CMP	Compliance Officer	48	13-04-30

Members of the board	Title	Age	Since
Kalpana Unadkat BRD	Director/Board Member	53	21-01-04
Prashant Gupta BRD	Director/Board Member	44	18-04-29
Amit Indubhushan Bakshi CEO	Chief Executive Officer	50	07-01-26
Kaushal Kamlesh Shah BRD	Director/Board Member	-	-
Inderjeet Singh Negi BRD	Director/Board Member	52	07-01-26
Sujesh Vasudevan BRD	Director/Board Member	58	22-07-24
Rajeev Dalal BRD	Director/Board Member	66	20-12-18
Krishnakumar Vaidyanathan COO	Chief Operating Officer	49	20-12-19

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	136,047,466	33,541,052 ( 24.65 %)	0	24.65 %

Name	Equities	%	Valuation
Amit Indubhushan Bakshi 42.88 %	58,335,144	42.88 %	588 M ₹
Emerald Investments Ltd. 7.581 %	10,312,132	7.581 %	104 M ₹
UTI Asset Management Co. Ltd. (Investment Management) 7.111 %	9,672,679	7.111 %	98 M ₹
HDFC Asset Management Co. Ltd. (Invt Mgmt) 6.597 %	8,973,322	6.597 %	91 M ₹
Rakeshbhai Bhikhabhai Shah 4.882 %	6,640,981	4.882 %	67 M ₹
Rajendra Rambhai Patel 4.367 %	5,939,834	4.367 %	60 M ₹
Inderjeet Singh Negi 4.367 %	5,939,833	4.367 %	60 M ₹
Bhikhabhai Chimanlal Shah 4.303 %	5,853,566	4.303 %	59 M ₹
Kaushal Kamlesh Shah 3.285 %	4,468,833	3.285 %	45 M ₹
Hetal Rasiklal Shah 2.615 %	3,557,520	2.615 %	36 M ₹

Eris Lifesciences Ltd.

Shivarth Ambit, Ramdas Road Off SBR, Near Swati Bungalows

380054, Ahmedabad

+91 79 6966 1000

http://www.eris.co.in

Name	Category and Sector
Eris Oaknet Healthcare Pvt Ltd. Eris Oaknet Healthcare Pvt Ltd. Pharmaceuticals: MajorHealth Technology Part of Eris Lifesciences Ltd., Eris Oaknet Healthcare Pvt Ltd. is an Indian pharmaceutical company that manufactures and supplies pharmaceutical products. The private company is based in Mumbai, India. The company was founded in 2015. The CEO is Raghav R S. Eris Oaknet Healthcare was acquired by Eris Lifesciences Ltd. on May 17, 2022 for $84.96 million.	Pharmaceuticals: Major

Name

Category and Sector

Pharmaceuticals: Major

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

881.6 INR

Average target price

1,081 INR

Spread / Average Target

+22.58%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+25.46%	659B
NOVO NORDISK A/S	+26.34%	557B
JOHNSON & JOHNSON	-4.86%	359B
MERCK & CO., INC.	+16.44%	322B
ABBVIE INC.	+8.34%	297B
ASTRAZENECA PLC	+6.58%	215B
NOVARTIS AG	+7.27%	210B
ROCHE HOLDING AG	-6.22%	200B
PFIZER, INC.	-8.79%	149B

Other Pharmaceuticals